

April 2020

Clinical Criteria updates

On August 16, 2019, the Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the **medical drug benefit** for Simply Healthcare Plans, Inc. and Clear Health Alliance. These policies were developed, revised or reviewed to support clinical coding edits.

Visit *Clinical Criteria* to search for specific policies. For questions or additional information, use this **email**.

Please see the explanation/definition for each category of *Clinical Criteria* below:

- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Annual review: minor wording and formatting updates, new document number
- Updates marked with an asterisk (*): Criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical policy. This does not apply to pharmacy services.

| Effective date | Document number | Clinical Criteria title | New, revised, annual review |
|----------------|-----------------|--|-----------------------------|
| May 29, 2020 | ING-CC-0142 | Somatuline Depot (lanreotide)* | New |
| May 29, 2020 | ING-CC-0143 | Polivy (polatuzumab vedotin-piiq)* | New |
| May 29, 2020 | ING-CC-0144 | Lumoxiti (moxetumomab pasudotox-tdfk)* | New |
| May 29, 2020 | ING-CC-0145 | Libtayo (cemiplimab-rwlc)* | New |
| May 29, 2020 | ING-CC-0030 | Implantable and ER Buprenorphine Containing Agents | Revised |
| May 29, 2020 | ING-CC-0036 | Naltrexone Implantable Pellets | Reviewed |
| May 29, 2020 | ING-CC-0107 | Bevacizumab for Non-Ophthalmologic Indications* | Revised |
| May 29, 2020 | ING-CC-0114 | Jevtana (cabazitaxel) | Revised |
| May 29, 2020 | ING-CC-0134 | Provenge (sipuleucel-T) | Revised |
| May 29, 2020 | ING-CC-0127 | Darzalex (daratumumab) | Revised |
| May 29, 2020 | ING-CC-0106 | Erbitux (cetuximab)* | Revised |

https://provider.simplyhealthcareplans.com/florida-provider https://provider.clearhealthalliance.com/florida-provider

Simply Healthcare Plans, Inc. is a Managed Care Plan with a Florida Medicaid contract. Clear Health Alliance is a Managed Care Plan with a Florida Medicaid contract. Simply Healthcare Plans, Inc. is a Medicare-contracted coordinated care plan that has a Medicaid contract with the State of Florida Agency for Health Care Administration to provide benefits or arrange for benefits to be provided to enrollees. Enrollment in Simply Healthcare Plans, Inc. depends on contract renewal.

IngenioRx, Inc. is an independent company providing pharmacy benefit management services on behalf of Simply Healthcare Plans, Inc. and Clear Health Alliance.

| Effective date | Document | Clinical Criteria title | New, revised, |
|----------------|-------------|---------------------------------------|---------------|
| | number | | annual review |
| May 29, 2020 | ING-CC-0105 | Vectibix (panitumumab) | Revised |
| May 29, 2020 | ING-CC-0124 | Keytruda (pembrolizumab) | Revised |
| May 29, 2020 | ING-CC-0128 | Tecentriq (atezolizumab) | Revised |
| May 29, 2020 | ING-CC-0104 | Levoleucovorin Agents | Reviewed |
| May 29, 2020 | ING-CC-0125 | Opdivo (nivolumab) | Revised |
| May 29, 2020 | ING-CC-0129 | Bavencio (avelumab) | Revised |
| May 29, 2020 | ING-CC-0130 | Imfinzi (durvalumab) | Revised |
| May 29, 2020 | ING-CC-0119 | Yervoy (ipilimumab) | Revised |
| May 29, 2020 | ING-CC-0094 | Alimta (pemetrexed disodium) | Revised |
| May 29, 2020 | ING-CC-0099 | Abraxane (paclitaxel, protein bound) | Revised |
| May 29, 2020 | ING-CC-0020 | Tysabri (natalizumab) | Revised |
| May 29, 2020 | ING-CC-0011 | Ocrevus (ocrelizumab) | Revised |
| May 29, 2020 | ING-CC-0009 | Lemtrada (alemtuzumab) | Revised |
| May 29, 2020 | ING-CC-0004 | H.P. Acthar Gel (repository | Revised |
| | | corticotropin injection) | |
| May 29, 2020 | ING-CC-0072 | Selective Vascular Endothelial Growth | Revised |
| | | Factor (VEGF) Antagonists* | |
| May 29, 2020 | ING-CC-0026 | Testosterone Injectable | Revised |
| May 29, 2020 | ING-CC-0008 | Subcutaneous Hormonal Implants | Revised |
| May 29, 2020 | ING-CC-0139 | Evenity (romosozumab-aqqg) | Revised |
| May 29, 2020 | ING-CC-0019 | Zoledronic Acid Agents | Revised |
| May 29, 2020 | ING-CC-0082 | Onpattro (patisiran)* | Revised |
| May 29, 2020 | ING-CC-0031 | Intravitreal Corticosteroid Implants* | Revised |
| May 29, 2020 | ING-CC-0084 | Tegsedi (inotersen)* | Revised |
| May 29, 2020 | ING-CC-0050 | Monoclonal Antibodies to | Revised |
| | | Interleukin-23* | |
| May 29, 2020 | ING-CC-0058 | Octreotide Agents* | Revised |
| May 29, 2020 | ING-CC-0022 | Vimizim (elosulfase alfa)* | Reviewed |